/
BCTX
$3.10+$0.04 (+1.31%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$26.6M
9M shares
52-week range
$2.60 – $31.10
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
27.18%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-739.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $16.9K | $18.8K | $18.7K | $15.6K | $15.1K | $15.5K | $82.6K | $147.9K |
| Gross profit | −$16.9K | −$18.8K | −$18.7K | −$15.6K | −$15.1K | −$15.5K | −$82.6K | −$147.9K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $3.1M | $4.9M | $3.0M | $2.5M | $10.3M | $20.5M | $27.2M | $29.5M |
| Operating income | −$5.0M | −$6.3M | −$5.3M | −$8.7M | −$19.6M | −$31.1M | −$33.3M | −$37.7M |
| EBITDA | −$5.4M | −$5.8M | −$4.8M | −$17.1M | −$34.4M | −$31.1M | −$4.8M | −$37.6M |
| Net income | −$5.4M | −$5.8M | −$4.9M | −$17.3M | −$34.4M | −$27.1M | −$4.8M | −$36.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1798.34 | -1505.30 | -5.64 | -13.50 | -259.50 | -195.00 | -43.01 | -62.60 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-11.45 | $-11.45–$-11.45 | 1 |
| 2027 | $10M | $-3.40 | $-3.40–$-3.40 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.15
Price
$3.10
Implied upside
+34%
Peer comparison
Briacell Therapeutics Corp. Common Shares
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
www.briacell.com- Employees
- 4
- IPO / List date
- Sep 5, 2023
- HQ
- WEST VANCOUVER, A1
Held by traders on TradeandTell
No one on the platform currently holds BCTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BCTX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-25 | 1-for-10reverse |
| 2025-01-29 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded BCTX yet.
